Ranibizumab outperforms laser in improving diabetic macular edema

08/26/2013 | MedPage Today (free registration)

Data on diabetic macular edema patients showed 49.1% of those on ranibizumab monotherapy attained at least a 5-point improvement in National Eye Institute Visual Functioning Questionnaire 25 composite scores after 12 months, compared with 42.7% of those on ranibizumab plus laser therapy and 30.6% of those on laser-only treatment. However, further analysis is required to determine whether the drug's benefits will be sustained during the three-year study period, researchers reported in JAMA Opthalmology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC